Compare Stocks: TIL, ABOS, TNXP, and VYGR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.65 +3.1%	$2.63	$1.22 ▼ $3.60	$191.64M	0.37	334,108 shs	889,887 shs
TIL Instil Bio	$7.09 -1.7%	$7.43	$5.67 ▼ $21.98	$48.08M	1.91	10,408 shs	27,516 shs
TNXP Tonix Pharmaceuticals	$10.87 -4.8%	$11.99	$9.40 ▼ $28.42	$186.43M	1.74	402,583 shs	807,907 shs
VYGR Voyager Therapeutics	$3.09 +1.6%	$3.23	$2.93 ▼ $5.55	$190.40M	1.32	403,889 shs	538,080 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	-9.25%	-16.93%	+17.26%	+112.00%
TIL Instil Bio	0.00%	-3.93%	-4.58%	-5.47%	-67.10%
TNXP Tonix Pharmaceuticals	0.00%	-8.42%	-12.27%	-9.49%	-60.77%
VYGR Voyager Therapeutics	0.00%	-3.13%	-6.93%	-16.94%	-27.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.65 +3.1%	$2.63	$1.22 ▼ $3.60	$191.64M	0.37	334,108 shs	889,887 shs
TIL Instil Bio	$7.09 -1.7%	$7.43	$5.67 ▼ $21.98	$48.08M	1.91	10,408 shs	27,516 shs
TNXP Tonix Pharmaceuticals	$10.87 -4.8%	$11.99	$9.40 ▼ $28.42	$186.43M	1.74	402,583 shs	807,907 shs
VYGR Voyager Therapeutics	$3.09 +1.6%	$3.23	$2.93 ▼ $5.55	$190.40M	1.32	403,889 shs	538,080 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	-9.25%	-16.93%	+17.26%	+112.00%
TIL Instil Bio	0.00%	-3.93%	-4.58%	-5.47%	-67.10%
TNXP Tonix Pharmaceuticals	0.00%	-8.42%	-12.27%	-9.49%	-60.77%
VYGR Voyager Therapeutics	0.00%	-3.13%	-6.93%	-16.94%	-27.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.60	Moderate Buy	$7.00	164.15% Upside
TIL Instil Bio	1.67	Reduce	$7.00	-1.27% Downside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	125.39% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	433.98% Upside

Current Analyst Ratings Breakdown

Latest TIL, ABOS, TNXP, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	ABOS Acumen Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	ABOS Acumen Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/15/2026	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
9/2/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A
TNXP Tonix Pharmaceuticals	$13.11M	14.22	N/A	N/A	$19.17 per share	0.57
VYGR Voyager Therapeutics	$40.37M	4.72	N/A	N/A	$3.53 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.63	N/A	N/A	N/A	N/A	-136.27%	-81.64%	11/11/2026 (Estimated)
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest TIL, ABOS, TNXP, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
8/12/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.21	2.47	2.47
TIL Instil Bio	0.79	21.67	21.67
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
TIL Instil Bio	60.56%
TNXP Tonix Pharmaceuticals	82.26%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
TIL Instil Bio	47.00%
TNXP Tonix Pharmaceuticals	2.00%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	61	72.32 million	64.94 million	Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Not Optionable
VYGR Voyager Therapeutics	141	61.62 million	53.79 million	Optionable

TIL, ABOS, TNXP, and VYGR Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR

September 4, 2026 | marketbeat.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened

August 29, 2026 | marketbeat.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 21, 2026 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | markets.businessinsider.com

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | globenewswire.com

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

June 10, 2026 | theglobeandmail.com

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

June 10, 2026 | tipranks.com

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

June 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TIL, ABOS, TNXP, and VYGR Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.65 +0.08 (+3.11%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.62 -0.02 (-0.94%)

As of 09/18/2026 07:41 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Instil Bio NASDAQ:TIL

$7.09 -0.12 (-1.66%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.11 +0.02 (+0.28%)

As of 09/18/2026 04:10 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tonix Pharmaceuticals NASDAQ:TNXP

$10.87 -0.55 (-4.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.96 +0.09 (+0.78%)

As of 09/18/2026 07:34 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Voyager Therapeutics NASDAQ:VYGR

$3.09 +0.05 (+1.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.07 -0.02 (-0.71%)

As of 09/18/2026 07:59 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TIL, ABOS, TNXP, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TIL, ABOS, TNXP, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TIL, ABOS, TNXP, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TIL, ABOS, TNXP, and VYGR Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Instil Bio NASDAQ:TIL

Tonix Pharmaceuticals NASDAQ:TNXP

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TIL, ABOS, TNXP, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TIL, ABOS, TNXP, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TIL, ABOS, TNXP, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TIL, ABOS, TNXP, and VYGR Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Instil Bio NASDAQ:TIL

Tonix Pharmaceuticals NASDAQ:TNXP

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools